DIAGNOSTIC BLOOD TEST Russian patent published in 2022 - IPC C12Q1/6883 

FIELD: biotechnology.

SUBSTANCE: invention relates to biotechnology, in particular, to a method for determining the degradation of the extracellular matrix (ECM) in a subject in vitro, wherein the method involves the determining, in a sample extracted from the subject, the level of the expression product of at least one gene selected from the group consisting of the collagen type V alpha-1 chain (COL5A1), transforming growth factor beta-1 (TGFB1), integrin alpha-4 subunit (ITGA4), integrin beta-1 subunit (ITGB1), matrix metallopeptidase 2 (MMP2), matrix metallopeptidase 9 (MMP9), and bone morphogenetic protein 1 (BMP1), wherein at least one gene is determined optionally in combination with one or both from the collagen type XI alpha-1 chain (COL11A1) and the collagen type V alpha-2 chain (COL5A2), wherein the level of the expression product(s) being higher than the reference value indicates a degraded ECM.

EFFECT: ensured determining of the degradation of the ECM in a subject.

10 cl, 6 dwg, 13 tbl, 2 ex